University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease : Analyses Conducted for Canada, France, Italy, and Portugal

Simple item page
dc.contributor.authorMaleki-Yazdi, M. Reza
dc.contributor.authorMolimard, Mathieu
dc.contributor.authorKeininger, Dorothy L
dc.contributor.authorGruenberger, Jean-Bernard
dc.contributor.authorCarrasco, Joao
dc.contributor.authorPitotti, Claudia
dc.contributor.authorSauvage, Elsa
dc.contributor.authorChehab, Sara
dc.contributor.authorPrice, David Brendan
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.date.accessioned2017-08-11T23:01:25Z
dc.date.available2017-08-11T23:01:25Z
dc.date.embargoedUntil2017-08-11
dc.date.issued2016-10
dc.descriptionAcknowledgments The authors would like to thank Purnima Pathak (Novartis) for providing writing assistance in the development of this manuscript. The authors would also like to thank Colin Burke and Ronan Mahon (Health Economic Modelers; Novartis) for their modeling support. Medical writing support was funded by Novartis Pharma AG (Basel, Switzerland).en
dc.description.statusPeer revieweden
dc.format.extent16
dc.format.extent205008
dc.identifier70096639
dc.identifierbe686c44-f5ce-400c-aecc-290d44092025
dc.identifier84981517775
dc.identifier.citationMaleki-Yazdi, M R, Molimard, M, Keininger, D L, Gruenberger, J-B, Carrasco, J, Pitotti, C, Sauvage, E, Chehab, S & Price, D B 2016, 'Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease : Analyses Conducted for Canada, France, Italy, and Portugal', Applied Health Economics and Health Policy, vol. 14, no. 5, pp. 579-594. https://doi.org/10.1007/s40258-016-0256-zen
dc.identifier.doi10.1007/s40258-016-0256-z
dc.identifier.iss5en
dc.identifier.urihttp://hdl.handle.net/2164/9140
dc.identifier.vol14en
dc.language.isoeng
dc.relation.ispartofApplied Health Economics and Health Policyen
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleCost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease : Analyses Conducted for Canada, France, Italy, and Portugalen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
LANTERN_multi_country_revised_MS_08032016_Copy.docx
Size:
200.2 KB
Format:
Unknown data format
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
8.29 KB
Format:
Plain Text
Description:
Download

Collections

All research
Applied Health Sciences research
University Office research